
Market Talk
Market Trades One Uncertainty for Another
Well folks, last week was quite a week on Wall Street.
The day after the November 3 blue wave election sweep, the stock market celebrated with a strong relief rally. But it didn't last long. The very next day, Thursday, November 5, Wall Street suffered a major selloff, with the S&P 500 experiencing its worst one-day decline since the April 2025 tariff turmoil.
And the numbers tell the story.
Wednesday, November 4 — The Relief Rally
Thursday, November 5 — The Selloff
In just one trading session, the market wiped out Wednesday's relief rally and then some. The Nasdaq suffered its worst daily decline in 19 months, entering correction territory.
By Friday, November 6, the market seemed to take a breather and return to something resembling normal trading. The Nasdaq recovered 1.1%, the S&P 500 gained 0.3%, while the Dow slipped another 0.5%.
But the tide remained out for many stocks in the aftermath, particularly those associated with artificial intelligence, semiconductors and the massive AI data-center buildout.
So what happened?
It appears Wall Street traded one uncertainty for another.
With the election behind us, investors initially welcomed the prospect of greater political clarity. But that optimism quickly gave way to new concerns about tighter regulation of AI, growing opposition to data-center expansion and whether the enormous amounts of money being poured into AI infrastructure can continue to support lofty stock valuations.
The election uncertainty may be behind us, but the uncertainty of the AI boom is another matter entirely. (But- The AI cat is out of the bag - and our adversaries likely won't slow it). Other uncertainties of war and peace along with social program spending, immigration policy, and tax and spend policies that may become prevalent as inexperienced legislators mistake TDS for a mandate to create ploicies that are against the U.S, constitution. It is doubfful here that Americans want to make the U.S, look like a socialized France that is now undergoing strife and turmoil from failed and "progressive" policy.
Let's Talk Strategy
So, picking up somewhere where we left off last week, let's talk strategy.
The last Jones Report listed some stocks we watch here, each with their own individual dynamics.
Now, we've already highlighted much of what makes these companies stand out, each with its own unique flair for potential outperformance.
But getting there, and the things that happen along the way, are what the market prices in on a daily basis.
Stocks can be as good as the belief in them, as good as their current performance, and as bad as the sentiment of the day.
And that sentiment can shift from darling to dog in a fickle world.
Fundamentals of earnings and growth, along with investor returns, still matter to traditional investors. But there are too many buts to mention here.
And now the political side of things has become even more uncertain.
There are many areas where politics overlaps business. AI data-center growth and regulation in the U.S. is just one example. Even the perception of a changing political tone is having a big negative effect on the technology sector lately.
Stock Talk
When market volatility like last week comes then resides, it's hard to know if the calm is brief like being in the eye of a hurricane.
In short, stocks require watching now if trading. Here, I'm using smaller "test positions" in some stocks.
One thing to notice is the semiconductor tech sector, for example, has herky-jerkily descended, down big one day, bouncing the next but not as much.
It's been like going three steps down a staircase and back up one.
This brings up suspicion of big money putting the shorts on.
When conflating conditions come, a smaller position to preserve buying power can preserve your cash arsenal of trading ammunition — that's dry powder.
One strategy here lately is by having small test positions, it "seems to" help awareness without losing so much skin that human emotion takes over the thinking. I posted the other day, about that. The goal became preserving the better gains of last year when opportunity is clearer.
Now some watch stocks have fallen to interesting levels. That doesn't necessarily mean they are all in full tilt buy situations.
Maybe some, or none till the weather clears.
The following is a list of a few stocks of interest to the Jones Report with recent changing dynamics. There will be more to report on, but these companies have been posted here before and can be found by scrolling through these freely given reports. If interested in any — remember the tenets here - maybe some, not too much, maybe start with small test positions even one or two shares or 100 shares if a speculative penny stock with big ideas.
Gold and Silver Miners: KGC, HL and CDE
Consumer stocks (w/dividend): KMB , CLX, MO
Semiconductors: NVTS, GFS, LRCX, KLAC (one or two shares?)
Defense: VVX ... and back on the watch list — KTOS
Speculative Biotech: XERS, CMPS, HELP, INO, ONCY
Anthropic IPO Play - maybe some SKM
Biotech Corner Notes:
The Biotech sector of healthcare can be an interesting one to follow regardless of the market volatility. There, individual companies can fly or fail based on their own achievements on bringing new drugs, new treatments to meet the ever-growing needs of human ailment.
As a few notes there was one biopharma that captured interest on the worse day of the market this year. The company XERS was added to the Jones watch list.
Xeris Biopharma Holdings, Inc. (XERS)
XERS management guided higher with somewhat astounding projection of over $1 billion in total annual revenue by 2030, with Recorlev potentially approaching $1 billion itself.
The XERS FDA approved drug to treat Cushing Syndrome. Even as the market cascaded lower, XERS surged a few points higher and it has sustained momentum. Such demand, if and as it plays out - could be a game changer for XERS stock.
Then we watched Inovio Pharmaceuticals (INO) as accelerated FDA approval was granted of a new DNA based approach to treat HPV related nodules and tumors in the respiratory tract. Clinical Data shows that significant relief was gained thereby reducing the need for costly surgery. There is an existing shot based on an adapted adenovirus approach that will compete, and both are expensive. Then last week, INO abruptly announced an offering that dilutes shares and at least temporarily quelling the levels. Well, INO needs the cash dearly to take the DNA approach to market. And the market and perhaps institutions or even bigger Pharma that wants a head start on DNA technology will step up. For now, the market put INO back under $2 a share.
All the listed biotechs in the Jones list are interesting, with possible catalysts approaching.
Often, stocks under $3 are called "penny stocks". One thing about the Jones report- sometimes we stay aware and open to the possibility and speculation on huge opportunity in stocks under $3 as we saw in the Quantum tech sector last year. However, the other side of the opportunity coin can be peril if not aware of the risk of "too much". "If and When" speculating - NOT too much - keep it fun and manage expectations along the way.
Long term gain is the notion even when short term pain persists in the market.
Stay Watchful.
- Jones Report
This site is just for fun and insight, with no sponsors and no affiliations. If you like this free Jones Report, tell a friend. Why not?
________
If interested - scroll back and view notes on other stocks, we watch here at the Jones report. Why not? With the caveat that things change and we try to stay aware - It's all FREE to read and make your own calls and decisions. Finally - maintain some dry powder and trade or invest according to your own due diligence.
______________
More later so ....Stay tuned, if you dare!
For now, we close by noting that any view on the market and stocks on any particular day may change in the days to come. That is why we watch and see how our views match up with reality. Looking ahead a few months may be a way to do things - but thinking too deeply about world events and the recent alliances forming, can make projecting ahead a dicey endeavor.
All in all - we use the word maybe "some", not "too much" and play it accordingly. Never get arrogant in our notions because things do change - and individual stocks are subject to many factors outside our control. So, we try to -stay aware.
With all the above caveats and attempted prognostications, I will close this post. Stay tuned for more opining on the market and stocks to watch.
___________
ALL in my humble opinion, scroll down and read more. This site does NOT make Buy / Sell recommendations.